Biora Therapeutics Inc
BIOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$994.99K
Close$
$-2.04
1028.4% downside
Current Fair Value
1028.4% downsideOvervalued by 1028.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $994,994.00 |
|---|---|
| Enterprise Value | $36.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-78.7 |
| Beta | 1.28 |
| Outstanding Shares | 3,652,862 |
Return
| Return on Equity | 29.58% |
|---|---|
| Return on Assets | -217.44% |
| Return on Invested Capital | 57.47% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 20.63 |
| Enterprise Value to EBIT | -0.6 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.06 |
| Debt to Equity | -0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 12, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.16%▲ 0.16% |
|---|---|
| Total Invested | $1,323 |
| Investors Holding | 1▲ 1.00% |
ESG Score
No data
About Biora Therapeutics Inc
642 employees
CEO: Harry Stylli Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro mo...